Biomarkers of response to combination cabozantinib + nivolumav in advanced renal cell carcinoma

Ended Project Grant Awarded Last action

Award ID
W81XWH2210523
Recipient
Awarding agency
Obligated
$1,342,500

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Funding
  • $671,250.00 Federal
  • $671,250.00 Non-federal
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of the Army Medical Command awarded $1,342,500 to Brigham & Women's Hospital Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "BIOMARKERS OF RESPONSE TO COMBINATION CABOZANTINIB + NIVOLUMAV IN ADVANCED RENAL CELL CARCINOMA" from July 1, 2022 to June 30, 2025.

Under this Project Grant award, Brigham & Women's Hospital will conduct research to investigate biomarkers of response to combination therapy with cabozantinib and nivolumab in treating advanced renal cell carcinoma. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will support the program's goal to investigate medical solutions for battlefield conditions by exploring an emerging treatment approach for a form of kidney cancer.

Quick answers

Who received award W81XWH2210523?

W81XWH2210523 was awarded to Brigham & Womens Hospital Inc. by Medical Command (Department of the Army) on July 1, 2022.

How much is award W81XWH2210523 worth?

$1,342,500 has been obligated on W81XWH2210523: $671,250 in federal funding and $671,250 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login